Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

Study (n=201) reports newly developed, tetravalent Ad26 vaccine was generally safe, well-tolerated, and found to elicit higher immune responses than trivalent regimen. Regimens using tetravalent vaccine component are being advanced into field trials to assess efficacy against HIV

Source:

The Lancet HIV